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CORRECTION
Bok is a genuine multi-BH-domain protein that triggers apoptosis
in the absence of Bax and Bak
Stephanie Einsele-Scholz, SilkeMalmsheimer, Katrin Bertram, Daniel Stehle, Janina Johänning, MarianneManz,
Peter T. Daniel, Bernhard F. Gillissen, Klaus Schulze-Osthoff and Frank Essmann
There was an error published in J. Cell Sci. 129, 2213–2223.
In Fig. 4A, a statement that duplicate α-tubulin blots are shown forMcl-1 and Bok, and for caspase-3 and Bax, because the samemembranes
were probed for these proteins, was inadvertently omitted from the legend.
The authors apologise to the readers for any confusion that this error might have caused.
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RESEARCH ARTICLE
Bok is a genuine multi-BH-domain protein that triggers apoptosis
in the absence of Bax and Bak
Stephanie Einsele-Scholz1, Silke Malmsheimer1, Katrin Bertram1, Daniel Stehle1, Janina Johänning1,
Marianne Manz1, Peter T. Daniel2,3, Bernhard F. Gillissen2,3, Klaus Schulze-Osthoff1,3,* and Frank Essmann1,3,*
ABSTRACT
The pro-apoptotic multidomain Bcl-2 proteins Bax and Bak (also
known as BAK1) are considered the gatekeepers of the intrinsic
pathway of apoptosis by triggering the mitochondrial release of
cytochrome c. The role of the third Bax- and Bak-homologous
multidomain protein Bok, however, is still unresolved. As cells doubly
deficient for Bax and Bak are largely resistant to various apoptotic
stimuli, it has been proposed that Bok is either dispensable for
apoptosis or that its role is dependent on Bax and Bak. Here, we
demonstrate, in several cell systems, that Bok efficiently induces
cytochrome c release and apoptosis even in the complete absence of
both Bak and Bax. Moreover, modulation of endogenous Bok levels
affects the apoptosis response. By RNA interference and targeted
deletion of the Bok gene, we demonstrate that Bok can significantly
influence the apoptotic response to chemotherapeutic drugs in
ovarian carcinoma cells. Hence, our results not only establish Bok
as a Bak- and Bax-independent apoptosis inducer, but also suggest a
potential impact of Bok expression in ovarian cancer therapy.
KEY WORDS: Apoptosis, Bok, Bcl-2-related ovarian killer, Matador,
Ovarian cancer
INTRODUCTION
Apoptosis is an evolutionary conserved process of altruistic cellular
suicide that can be induced by extra- and intra-cellular stress stimuli.
Irrespective of the initiating upstream signal, apoptosis culminates
in the activation of cell-death-specific cysteinyl aspartases, called
caspases (Los et al., 1999). Caspase activation occurs in response to
ligation of death receptors on the plasma membrane (extrinsic
pathway) or following the release of cytochrome c from the
mitochondrial intermembrane space (intrinsic pathway). The release
of cytochrome c is regulated by members of the Bcl-2 family of
proteins and decisively depends on the presence of multidomain
proteins (MDPs) of the Bcl-2 family, that is, Bax or Bak (also
known as BAK1) (Wei et al., 2001; Shamas-Din et al., 2013). The
pro-apoptotic activity of Bax and Bak is counteracted by anti-
apoptotic ‘Bcl-2-like’ members, such as Bcl-2, Bcl-xL (a splice
variant encoded by BCL2L1), Bcl-w (also known as BCL2L2),
Mcl-1 and A1 (also known as BCL2A1) (Chi et al., 2014). The anti-
apoptotic Bcl-2 proteins can be inhibited in turn by a third subgroup,
the Bcl-2 homology domain 3 (BH3)-only proteins, such as Bad,
Bid, Bik (also known as Nbk), Bim (also known as BCL2L11),
Noxa (also known as PMAIP1), Puma (also known as BBC3), Hrk
and Bmf (Delbridge et al., 2016). Bcl-2 proteins form an intricate
network that regulates apoptosis by direct protein interaction. The
interaction of BH3-only proteins and anti-apoptotic proteins has
been studied in great detail (Willis et al., 2007). Thus, it has been
shown that Bim, Bid and Puma potently bind to each anti-apoptotic
Bcl-2 protein, whereas other BH3-only proteins specifically interact
with a subset of anti-apoptotic proteins. Certain BH3-only proteins,
especially the caspase-cleaved truncated form of Bid and Puma,
have been shown to directly interact and thereby activate Bax or Bak
through induction of a conformational change and oligomerization
(Kuwana et al., 2005; Du et al., 2011; Westphal et al., 2014). In
addition, anti-apoptotic Bcl-2-like proteins differ in their binding
specificity to Bax or Bak. Whereas Bax binds to Bcl-2 and Bcl-xL,
the homologous protein Bak preferentially binds to Mcl-1 and
Bcl-xL (Gillissen et al., 2007).
It is widely accepted that mouse embryonic fibroblasts (MEFs)
frommice that are null for bothBax andBak (denotedBax−/−/Bak−/−)
or cells deficient for Bax and Bak, such as HCT116 Bax−/−/Bak−/−
cells, are largely resistant to a wide variety of pro-apoptotic stimuli
(Wei et al., 2001; Wang and Youle, 2012). Consequently, the
multidomain proteins Bax and Bak are considered indispensable for
cytochrome c release and apoptosis induction through the intrinsic
pathway.However, the fact that Bax−/−/Bak−/− double-knockoutmice
can be born viable, although at a reduced rate (Lindsten et al., 2000),
indicates that apoptosis during embryonic development of certain
organs is dispensable, replaced by another mode of cell death or that
alternativemechanisms compensate for the loss of Bax andBak. Such
a compensatory mechanism might be attributed to the third, largely
unknown, multidomain protein Bcl-2-related ovarian killer (Bok)
(Hsu et al., 1997; Inohara et al., 1998). Bok is evolutionary conserved
and homologous to Bax and Bak (Zhang et al., 2000). Surprisingly, in
contrast to the vast number of investigations on Bax and Bak, only
limited work has been devoted to investigate the regulation and
function of Bok. Bok is widely expressed, particularly in reproductive
tissues, but its loss has apparently only minimal impact in mice (Ke
et al., 2012). Even the combined deficiency of Bok in Bax or Bak
single-knockout mice does not show additional phenotypic alterations
as compared to the parental mouse strain (Ke et al., 2013).
Initially, Bok was assumed to function similarly to Bax and Bak,
because it also forms clustered structures at the mitochondrial outer
membrane that are associated with cytochrome c release (Gao et al.,
2005). Because these experiments were performed in MCF7 cells,
which are proficient in Bax and Bak (Neise et al., 2008), Bok might
function as a BH3-only protein, for example, like Puma (Jabbour
et al., 2008), and induce cytochrome c release indirectly by blockingReceived 5 October 2015; Accepted 11 April 2016
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anti-apoptotic proteins or by directly activating Bax and Bak, which
in turn mediate cytochrome c release. This is supported by
experiments showing that Bok alone is insufficient for apoptosis
induction in Bax−/−/Bak−/− MEFs and that Bok depends on Bax
and Bak to mediate release of cytochrome c (Echeverry et al., 2013).
However, it should be considered that the inability of endogenous
Bok tomediate apoptosis in the absence of Bax and Bakmight be due
to its low or even absent expression level inMEFBax−/−/Bak−/− cells
(Echeverry et al., 2013; Llambi et al., 2016). In addition to
mitochondria, a fraction of Bok is localized to the Golgi and ER,
implying a potential role of Bok in ER-stress-induced apoptosis
(Echeverry et al., 2013; Carpio et al., 2015; Llambi et al., 2016).
Furthermore, in several human cancers, including ovarian and breast
carcinoma, the genomic locus encoding Bok is frequently deleted,
suggesting a potential role of Bok as a tumor suppressor, similar to
Bax and Bak (Beroukhim et al., 2010).
Despite its early discovery, Bok is certainly the most poorly
understood Bcl-2 protein and its physiological role remains
enigmatic. We, therefore, set out to characterize the pro-apoptotic
function of Bok and the relevance of Bok for apoptosis sensitivity
towards anti-cancer drugs. We found that overexpression of Bok
strongly induced apoptosis accompanied by oligomerization of Bax
and Bak. Interestingly, in Bax- and Bak-deficient cells Bok
expression also efficiently induced the release of cytochrome c,
meaning that Bok is a genuine pro-apoptotic multidomain protein.
Consequently, downregulation of endogenous Bok expression, as
well as targeted disruption of the Bok gene, effectively reduced the
apoptosis sensitivity of even Bax- and Bak-proficient cells. Hence,
Bok is a relevant component of the Bcl-2 network and, therefore, a
potential target for anti-cancer therapeutic approaches.
RESULTS
Overexpression of Bok activates Bax and Bak and induces
cytochrome c release
It has been previously shown that, in MCF7 cells, overexpressed
EGFP–Bok displays clustered signals at the mitochondria that are
associated with the release of cytochrome c from the mitochondrial
intermembrane space (Gao et al., 2005). Because MCF7 cells
express both Bax and Bak (Neise et al., 2008), the release of
cytochrome cmight be mediated either directly by Bok or indirectly
by Bok-induced activation and oligomerization of Bax and/or Bak.
In order to investigate these possibilities in further detail, we
transfected MCF7 cells with pEGFP-Bok and performed
immunofluorescence microscopy, detecting active Bax and Bak
with conformation-specific antibodies, in parallel with detection of
the mitochondrial marker Tom20. As a control, we also transfected
MCF7 cells with pEGFP-Bax or pEGFP-Bak. Immunofluorescence
microscopy showed that clustered EGFP signals of either protein
coincided with the detection of active conformations of endogenous
Bax and Bak (Fig. 1A,B). Interestingly, Bax and Bak mainly
colocalized, whereas EGFP–Bok colocalized with active Bax or
active Bak to a lower extent. Immunoblot analysis, however,
verified that Bok was clearly detectable in mitochondria-enriched
subcellular fractions in transfected MCF7 and HEK293 cells
(Fig. S1A). Moreover, co-staining for the ER marker calnexin
revealed that Bok was also partially localized at the ER (Fig. S1B),
consistent with the reported broader localization of Bok at
intracellular membranes (Echeverry et al., 2013). Next, we again
transfected MCF7 cells with pEGFP-Bax, -Bak or -Bok and
detected active Bax or Bak in parallel to cytochrome c. As already
indicated by the clustering of endogenous Bax and Bak in response
to overexpressed Bax, Bak and Bok, we found that cytochrome c
was readily released from the mitochondria in MCF7 cells with
clustered Bax, Bak and also Bok (Fig. 1C,D).
Overexpression of Bok induces cell death in the combined
absence of Bax and Bak
Having shown that overexpression of Bok is accompanied by
activation of Bax and Bak as well as by the release of cytochrome c,
we next investigated whether Bax and Bak are necessary for Bok-
mediated mitochondrial alterations. To this end, we transfected
wild-type and Bax−/−/Bak−/− HCT116 cells (denoted HCT116/wt
and HCT116/Bax−/−/Bak−/−, respectively) (Wang and Youle,
2012) with pEGFP-Bok or the pEGFP empty control and
subsequently used fluorescence-activated cell sorting (FACS)
analysis to assess cell death induction in EGFP-expressing cells
by Sytox Red staining. Overexpression of EGFP–Bok was clearly
associated with cell death induction both in HCT116/wt and
HCT116/Bax−/−/Bak−/− cells. Despite similar levels of Bok
expression, as revealed by FACS analysis, Bok induced cell death
slightly less efficiently in HCT116/Bax−/−/Bak−/− (24 h, 24%;
48 h, 40%) as compared to HCT116/wt (24 h, 28%; 48 h, 55%)
cells (Fig. 2A). To exclude the possibility that the weaker cell death
induction in HCT116/Bax−/−/Bak−/− cells was due to enhanced
expression of anti-apoptotic proteins, we performed immunoblot
analysis verifying a largely similar expression of anti-apoptotic
proteins in HCT116/Bax−/−/Bak−/− and HCT116/wt cells (Fig. 2B).
Although overexpression of Bok efficiently induced cell death in
HCT116/Bax−/−/Bak−/− cells, we wanted to confirm Bax- and Bak-
independent cell death in another cellular system. Experiments in
MEFs fromBax−/−/Bak−/−mice demonstrated cytochrome c release
upon Bok expression (Fig. S1C); however, in our hands the cells
showed a poor transfection efficiency. We therefore used baby
mouse kidney (BMK) cells from Bax−/−/Bak−/− mice (Degenhardt
et al., 2002). These cells also are deficient for Bax and Bak but show
high expression of the anti-apoptotic proteins Bcl-2 and Mcl-1
(Fig. 2B) and are more efficiently transfected. Cell death induced by
overexpression of EGFP-tagged Bax, Bak or Bok was quantified by
measuring lactate dehydrogenase (LDH) release (Fig. 2C). In
accordance with results from HCT116/Bax−/−/Bak−/− cells, BMK/
Bax−/−/Bak−/− cells also readily died upon overexpression of any of
the multidomain proteins, including Bok.
Bok induces apoptosis in the absence of Bax and Bak
We showed above that Bok expression efficiently induces cell death
in the absence of Bax and Bak both in human HCT116 cells and in
murine BMK cells. We next analyzed cell death induction in BMK
cells after transfection with pEGFP-Bax, -Bak and -Bok by FACS
analysis of EGFP-positive cells in more detail. Flow cytometric
analysis of Sytox-Red-stained cells revealed that, at 24 h post
transfection, pEGFP-Bok induced cell death in 22% of the EGFP-
positive cells, which was lower as compared to that induced by
EGFP–Bak (42%) and EGFP–Bax (>55%) (Fig. 3A). After 48 h,
the proportion of EGFP–Bax- or EGFP–Bak-expressing Sytox-
Red-positive cells was similar (∼55%) and the number of Sytox-
Red-positive, EGFP-Bok-expressing BMK cells was 33%. In each
case, the caspase inhibitor Q-VD-OPh significantly reduced the
number of EGFP-expressing Sytox-Red-positive cells, indicating
caspase-dependent (i.e. apoptotic) cell death (Fig. 3A).
In an analogous set of experiments, we investigated exposure of
phosphatidylserine at the outer leaflet of the plasma membrane, a
common marker of apoptosis. Cells were transfected with the
respective expression constructs and, after staining with annexin V,
were analyzed by flow cytometry (Koopman et al., 1994). These
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analyses showed that overexpression of any of the multidomain
proteins (i.e. EGFP-tagged Bax, Bak and Bok), induced
phosphatidylserine exposure at 24 h and 48 h post transfection
(Fig. 3B), which was blocked by the caspase inhibitor Q-VD-OPh.
In linewith theSytoxRed staining, expression ofBax andBak resulted
in an increased number of annexin-V-positive BMKcells as compared
to the expression of Bok. A more detailed analysis revealed that
indeed, at similar intensities of the EGFP signal, apoptosis induction
was stronger in Bax- and Bak- than in Bok-expressing cells (Fig. S2).
Although phosphatidylserine exposure at the cell surface is an
early marker of apoptosis, it occurs downstream of caspase
activation. Caspase activation in intrinsic apoptosis signaling
is induced by the mitochondrial release of cytochrome c and is
associated with loss of the mitochondrial membrane potential
(ΔΨm). To investigate whether the mitochondrial transmembrane
potential declines in response to overexpression of EGFP–Bok, we
used TMRE staining and flow cytometric analysis. Overexpression
of EGFP–Bok, similar to EGFP–Bax and EGFP–Bak, was
accompanied by low TMRE fluorescence, indicating a reduction
of ΔΨm (Fig. 3C). Bok expression in the presence of the caspase
inhibitor Q-VD-OPh reduced the number of EGFP-positive cells
with low ΔΨm (Fig. 3C), which is consistent with a caspase
dependency for the loss ΔΨm (Ricci et al., 2003).
In addition to flow cytometric analyses, Bok-mediated apoptosis
induction was confirmed by analysis of caspase-3 and lamin A/C
cleavage. Immunoblot analysis revealed processing of pro-caspase-
Fig. 1. EGFP–Bok forms clusters at mitochondria and triggers activation of Bax and Bak and cytochrome c release. MCF7 cells were transfected with
plasmids for the expression of EGFP fusion proteins of Bax, Bak and Bok. After 16 h, cells were analyzed by immunofluorescence microscopy for the
mitochondrial marker Tom20 (A,B), cytochrome c (C,D) and the respective EGFP fusion proteins. The active forms of Bax (A,C) and Bak (B,D) were detected by
conformation-specific antibodies against the N-terminus (NT) of the proteins.
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3 to the p17 subunit and cleavage of the caspase-6 substrate lamin
A/C in response to EGFP-tagged Bok, as well as Bak and Bax,
expression, which was efficiently blocked by Q-VD-OPh (Fig. 3D).
Finally, in line with the results in HCT116 cells, BMK cells
overexpressing EGFP-tagged Bax, Bak and also Bok displayed
mitochondrial release of cytochrome c, as assessed by
immunofluorescence microscopy (Fig. 3E) and flow cytometry
(Fig. 3F). Hence, Bok expression in Bax−/−/Bak−/− BMK cells
induced each apoptosis-associated hallmark that has been ascribed
to the activity of the pro-apoptotic multidomain proteins Bax and
Bak. Apoptotic alterations, such as caspase activation, in the
absence of Bax and Bak were not only observed upon expression of
EGFP-tagged Bok, but also when a Bok version with a smaller Flag
tag was used (Fig. S3).
Bok knockdown reduces the apoptosis sensitivity of ovarian
carcinoma cells
Having established that there is a Bax- and Bak-independent pro-
apoptotic function of Bok in overexpression experiments, we next
analyzed whether Bok is functionally relevant for apoptosis
induction. For these analyses, we chose ovarian cancer cell lines
that revealed significant endogenous expression of Bok. As shown
by immunoblot analysis, all cell lines (OVCAR-3, -4, -8) expressed
Bok as well as Bax, Bak and caspase-3 (Fig. 4A). The cell lines also
expressed the anti-apoptotic proteins Bcl-2, Bcl-xL and Mcl-1,
although in varying amounts.
In order to analyze a role of Bok in apoptosis sensitivity, we
performed small interfering RNA (siRNA)-mediated Bok
knockdown (siBok) and subsequently induced apoptosis by drug
treatment with cis-diaminodichloroplatinum(II) (cisPt, 40 µM),
taxol (0.1 µM) or camptothecin (1.0 µM). At 48 h after
transfection with Bok-specific or control siRNAs, cells were
exposed to the respective drugs for 24 h, before caspase
(DEVDase) activity was assessed in cell lysates by a
luminometric substrate assay. DEVDase activity induced by cisPt
and taxol was reduced by ∼20% in siBok-transfected OVCAR-3
and -4 cells as compared to control-siRNA-transfected cells
(Fig. 4B). Knockdown of Bok reduced the DEVDase activity in
response to camptothecin treatment even more efficiently, by almost
30% in OVCAR-3 and 35% in OVCAR-4 cells (Fig. 4B). Reduction
of drug-induced caspase activation upon Bok knockdown was most
pronounced in OVCAR-8 cells, which showed 35% (cisPt), 36%
(taxol) and 32% (camptothecin) less DEVDase activity after
incubation with the chemotherapeutic drugs (Fig. 4B).
Furthermore, we compared the effect of Bok knockdown with
that of Bax and Bak in OVCAR-8 cells. Immunoblot analysis
confirmed an efficient knockdown of each pro-apoptotic
multidomain protein (Fig. 4C, upper panel) and revealed
concomitantly reduced activation-associated cleavage of pro-
caspase-3 after incubation with cisPt, taxol or camptothecin
(Fig. 4C, lower panel). Whereas the reduction of caspase-3
cleavage in camptothecin- and taxol-treated OVCAR-8 cells upon
the knockdown of Bok, Bak and Bax was similar, cisPt-induced
caspase-3 processing was efficiently reduced by the knockdown of
Bok or Bak and slightly by the knockdown of Bax (Fig. 4C, lower
panel). In line with reduced caspase-3 processing, lysates from
OVCAR-8 cells transfected with siRNA against Bak and Bok
(siBak and siBok, respectively) also showed reduced DEVDase
activity in response to drug treatment (Fig. 4D). As siBok and siBak
individually protected cells from drug-induced cell death, we
performed simultaneous knockdown of both Bok and Bak, and
analyzed caspase activation in response to drug treatment. The
Fig. 2. Bok induces cell death in the absence of Bax and Bak. (A) HCT116/
wt and HCT116/Bax− /−/Bak− /− were transfected with expression plasmids
for EGFP (ctrl) or EGFP–Bok. At 24 or 48 h after transfection, EGFP-positive
dead cells were detected by flow cytometric analysis of Sytox Red
staining. (B) Immunoblot analysis confirms Bax and Bak knockout in HCT116/
Bax− /−/Bak− /− (–/–) and BMK cells and expression of anti-apoptotic proteins
Bcl-2, Bcl-xL, Bcl-w and Mcl-1. (C) Overexpression of EGFP–Bax, EGFP–Bak
and EGFP–Bok induces LDH release in BMK cells that is blocked by the
caspase inhibitor Q-VD-OPh (QVD). Data indicate the fold release of LDH into
supernatants relative to the EGFP-only control. Results in panels A and C
show the mean±s.d. from three independent experiments. *P≤0.05, **P≤0.01;
n.s., not significant (unpaired two-tailed Student’s t-test).
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Fig. 3. Overexpressed EGFP–Bok induces apoptosis in Bax and Bak doubly deficient BMK cells. BMK cells were transfected with expression constructs for
EGFP (ctrl), EGFP–Bax, EGFP–Bak or EGFP–Bok and cultured for 24 h or 48 h in the presence or absence of Q-VD-OPh (QVD). Cells were analyzed for Sytox
Red (A), annexin V (B) or TMRE (C) staining in the EGFP-positive cell population. (D) Immunoblot analysis of EGFP–Bax-, EGFP–Bak- and EGFP–Bok-
expressing cells reveals activation-associated cleavage of pro-caspase-3 and cleavage of the caspase-6 substrate lamin A/C (asterisk indicates EGFP signal).
(E) BMK cells transfected with pEGFP-Bax, -Bak or -Bok were stained for the mitochondrial protein Tom20 (blue) and cytochrome c (red). Immunofluorescence
microscopy shows cytosolic cytochrome c in cells with clustered EGFP signals of the Bax, Bak and Bok proteins. (F) Flow cytometric analysis of transfected
BMKcells shows reduced cytochrome c signal intensity in EGFP-tagged cells expressingBax,Bak andBok as compared toEGFP-expressing control cells. Results
in panels A–C, F show the mean±s.d. from three or more independent experiments. *P≤0.05, **P≤0.01, ***P≤0.001; n.s., not significant (unpaired two-tailed
Student’s t-test).
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Fig. 4. Knockdown of Bok reduces
drug-induced apoptosis in ovarian
carcinoma cells. (A) Immunoblot
analyses demonstrating expression
of the pro-apoptotic multidomain
proteins Bax, Bak and Bok, the anti-
apoptotic proteins Bcl-2, Bcl-xL and
Mcl-1, and pro-caspase-3 in OVCAR-
3, OVCAR-4 and OVCAR-8 cells.
(B) Bok knockdown results in
reduced caspase activity. Bok was
knocked down in OVCAR-3, OVCAR-
4 and OVCAR-8 cells, before cells
were cultured in the presence of cisPt
(24 h), taxol (48 h) or camptothecin
(24 h). Caspase (i.e. DEVDase
activity) was analyzed by the
CaspaseGlo 3/7 assay and is given
as percentage of DEVDase activity
from cells transfected with a non-
targeting control siRNA (siNT).
Knockdown of Bok was verified by
immunoblot analysis. (C,D) Bok, Bak
and Bax were knocked down in
OVCAR-8 cells and cells were
incubated with cisPt, taxol or
camptothecin. Knockdown of Bok
and Bak, and to aminor extent of Bax,
is associated with reduced caspase-3
cleavage (C) and reduced DEVDase
activity (D) after incubation with the
cytotoxic drugs. (E) Combined
knockdown of Bok and Bak enhances
inhibition of DEVDase activity in
OVCAR-8 cells in response to cisPt
(left panel) and to a lesser extent to
taxol (middle panel) and
camptothecin (right panel).
Knockdown of Bok and Bak and
cleavage of pro-caspase-3 was
analyzed by immunoblotting (lower
panels). Downregulation of Bok and
Bak expression resulted in reduced
pro-caspase-3 processing. Results in
panels B, D and E show the mean±
s.d. from at least three experiments.
*P≤0.05, **P≤0.01; n.s., non-
significant (unpaired two-tailed
Student’s t-test).
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simultaneous knockdown of Bok and Bak led to an enhanced
inhibition of cisPt-induced DEVDase activity and caspase-3
cleavage (Fig. 4E).
Bok knockout diminishes apoptosis induction by cytostatic
drugs in OVCAR-8 cells
The previous knockdown experiments support a functional
relevance of Bok for apoptosis sensitivity of ovarian carcinoma
cells. We next sought to confirm these results in a suitable knockout
rather than knockdown system. To this end, we employed
transcription-activator-like effector nuclease (TALEN) technology
and co-transfected OVCAR-8 cells with vectors targeting exon 1 of
the Bok gene and a DNA-cleavage-sensitive reporter construct that
allowed the enrichment of gene-modified cells (Sun and Zhao,
2013). After transfection with both plasmids, individual cells that
simultaneously expressed GFP and RFP were FACS-sorted into a
96-well plate. We chose three clonal cell lines devoid of Bok
expression as detected by immunoblot analysis (Fig. 5A).
Moreover, DNA sequence analysis confirmed frameshift
mutations in each clonal cell line, resulting in a stop codon in the
TALEN-targeted exon of Bok (Fig. S4). In contrast to Bok, the
expression level of other apoptosis-relevant proteins (i.e. Bak, Bax,
Bcl-xL, Bcl-2 andMcl-1) remained unaltered in the three cell clones
as compared to the parental cell line (Fig. 5A), thereby excluding
off-target effects.
We next compared the sensitivity towards drug-induced
apoptosis of the generated OVCAR-8 Bok−/− cells with the
parental cell line. As expected, each of the three individual
OVCAR-8 Bok−/− cell lines showed reduced DEVDase activity
and caspase-3 cleavage after incubation with cisPt, taxol and
camptothecin as compared to parental OVCAR-8 cells (Fig. 5B).
Because expression of anti-apoptotic proteins was not enhanced and
expression of Bax and Bak was also not affected, the reduced
sensitivity of OVCAR-8 Bok−/− cells can be attributed to the
absence of Bok. In addition, upon drug treatment, the Bok
deficiency of OVCAR-8 cells resulted in a significant reduction
of annexin-V-positive early apoptotic cells as well as secondary
necrotic cells (Fig. 5C). A reduced drug sensitivity upon Bok
ablation was not restricted to ovarian cancer cells, but also observed
in SH-SY5Y neuroblastoma cells following siRNA-mediated
knockdown of Bok (Fig. 5D).
DISCUSSION
Members of the Bcl-2 family are crucial regulators of the intrinsic
apoptosis pathway that act by controlling the mitochondrial release
of cytochrome c (Czabotar et al., 2014; Moldoveanu et al., 2014).
Research over the past 30 years has unveiled a complex interaction-
based network of Bcl-2 proteins (Chi et al., 2014; Delbridge et al.,
2016). Whereas many BH3-only proteins merely inhibit anti-
apoptotic Bcl-2 proteins, distinct BH3-only proteins catalyze the
recruitment and insertion of Bax or Bak into the outer mitochondrial
membrane. The Bax and Bak homolog Bok has largely slipped
attention, most likely due to its low expression level in commonly
used cell lines as compared to Bax and Bak. Additionally, the Bok-
knockout mouse strain generated by Ke et al. does not present an
overt phenotype and even the phenotypes of Bok and Bax, and Bok
and Bak double-knockout strains do not significantly differ from
Bax or Bak single-knockout mice, allegedly underlining an
insignificant role for Bok (Ke et al., 2012, 2013).
In line with the homology of Bok to Bax and Bak, we found that
enforced Bok expression was able to induce classical apoptosis
hallmarks associated with cytochrome c release. Interestingly, Bok
expression also triggered mitochondrial clustering of Bax and Bak
signals reflecting their oligomerization and activation state. There
are several possibilities to explain the downstream Bax and Bak
activation. For instance, through its own conserved BH3 domain,
Bok might act itself like a BH3-only protein and directly activate
Bax and Bak or neutralize anti-apoptotic Bcl-2 proteins, leading to
BH3-only protein release, and Bax and Bak activation. In addition,
Bok might form heterodimers with Bax and/or Bak, although
previous studies failed to demonstrate a direct interaction of Bok
with other multidomain proteins (Carpio et al., 2015).
At first view, Bok-mediated downstream activation of Bak and
Bax is consistent with earlier assumptions claiming that Bok-
induced apoptosis is dependent on Bax and Bak. Thus, it has been
reported that enforced expression of Bok activates the intrinsic
apoptotic pathway in Bax- and Bak-proficient cells, but fails to kill
cells lacking both Bax and Bak or sensitize them to cytotoxic insults
(Echeverry et al., 2013). In line with this report, we also detected a
certain portion of Bok not only at mitochondria, but also at the ER,
as revealed by co-localization with the ER marker calnexin. It has
been recently suggested that Bok might exert a selective role in ER-
stress-induced Bax and Bak activation, and promotion of
mitochondrial apoptosis, as Bok−/− cells have been found to be
defective in their response to ER stress stimuli (Carpio et al., 2015).
The contribution of Bok to ER-stress-induced apoptosis, however,
remains controversial, as other studies have detected no differences
of Bok-deficient cells in their sensitivity to ER stress or have even
reported that brefeldin-A-treated cells died faster in the absence of
Bok (Fernandez-Marrero et al., 2016; Echeverry et al., 2013). A
recent study that appeared during revision of this manuscript further
suggested that Bok plays a selective role for apoptosis in response to
proteasome inhibition or ER-associated protein degradation
(ERAD) dysfunction (Llambi et al., 2016).
In several cellular systems, we clearly demonstrate a pro-
apoptotic role for Bok. A functional role of Bok is not only
evident in overexpression experiments, but also by our finding that
siRNA-mediated knockdown of endogenous Bok in three different
ovarian cancer cell lines, as well as in neuroblastoma cells, could
significantly protect against apoptosis induced by different
chemotherapeutic drugs. The RNA interference or overexpression
experiments do certainly not exclude that Bok, through its own BH3
domain, might act in a similar manner as classical BH3-only
proteins. However, our experiments in MEFs, HCT116 and BMK
cells clearly reveal that Bok can act as a bona fide multidomain
protein and induce apoptosis in the absence of Bak and Bax, a
finding supported by the recent study of Llambi et al. (2016).
Moreover, TALEN-mediated Bok knockout in ovarian cancer cells
lowered the sensitivity to drug-induced apoptosis. These results
seem to contradict previous findings that failed to detect altered
apoptosis sensitivity in the absence of Bok (Ke et al., 2012;
Echeverry et al., 2013). In contrast to the ovarian cancer cells or SH-
SY5Y neuroblastoma cells with a strong Bok expression, however,
previous studies employed MEFs or lymphocytes with rather low
endogenous Bok levels, whose downregulation might not affect the
apoptotic response.
The Bok gene locus is frequently deleted in human cancer
(Beroukhim et al., 2010). This finding, as well as our result that
reduced or absent expression of Bok affects apoptosis sensitivity in
response to conventional chemotherapeutic drugs, suggest, at least
in ovarian cancer, that Bok expression might be relevant for cancer
therapy. The proteins Bax and Bak show a specific yet overlapping
interaction pattern, with Bax preferentially binding to Bcl-2 and
Bcl-xL, whereas Bak primarily interacts with Bcl-xL and Mcl-1
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Fig. 5. Inhibition of Bok expression attenuates sensitivity
of OVCAR-8 and SH-SY5Y cells to drug-induced
apoptosis. (A) Western blot analysis confirms TALEN-
mediated loss of Bok expression in three OVCAR-8 Bok-
knockout clones, whereas expression of Bax, Bak Bcl-2, Bcl-xL
and Mcl-1 was similar to that in parental wild-type OVCAR-8
cells (wt). (B) Induction of DEVDase activity (upper panels)
and pro-caspase-3 cleavage (lower panels) by treatment with
cisPt (24 h), taxol (48 h) and camptothecin (24 h) is markedly
reduced in Bok-knockout cell lines. (C) OVCAR-8/wt and Bok-
knockout clones were incubated in the presence of cisPt
(80 µM), taxol (0.1 µM) or camptothecin (1.0 µM) for 48 h. ctrl,
cells incubated with with 0.1% DMSO. Cells were stained with
annexin-V–FITC and propidium iodide (PI) and analyzed by
flow cytometry. (D) SH-SY5Y cells were transfected with Bok-
specific or a non-targeting siRNA control (siNT) before
incubation in the presence of cisPt (20 µM), taxol (0.05 µM) or
camptothecin (0.5 µM) for 24 h. Flow cytometric analysis of
annexin V and propidium iodide staining shows that Bok
knockdown (upper panels) results in a reduced number of
annexin-V-positive and annexin V and propidium iodide
double-positive SH-SY5Y cells. Representative dot blots are
shown on the left. Efficient Bok knockdown was verified by
immunoblot analysis. Results in panels B,C and D show the
mean±s.d. from at least three independent experiments.
*P≤0.05, **P≤0.01, ***P≤0.001 (unpaired two-tailed
Student’s t-test).
2220
RESEARCH ARTICLE Journal of Cell Science (2016) 129, 2213-2223 doi:10.1242/jcs.181727
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
(Willis et al., 2005; Llambi et al., 2011). Hence, small-molecule
drugs such as ABT-737, ABT-263 and ABT-199, which bind to and
inhibit the anti-apoptotic activity of Bcl-2, or A-1210477, which
targets Mcl-1, are highly promising drugs in cancers with Bcl-2 or
Mcl-1 overexpression (Leverson et al., 2015). Mcl-1 and also A1
have been shown to interact with Bok and to prevent Bok-induced
apoptosis after overexpression (Hsu et al., 1997; Inohara et al., 1998,
and data not shown). In addition, Bok overexpression has been
found to kill Mcl-1-deficient MEFs significantly faster than wild-
type cells (Echeverry et al., 2013). Therefore, the Mcl-1 inhibitor A-
1210477 or an A1 inhibitor might sensitize Bok-proficient tumors
to apoptosis induction. Intriguingly, as we show an autonomous
function of Bok for cytochrome c release and apoptosis in the
absence of Bax and Bak, such drugs might be even effective in Bax-
and/or Bak-deficient tumor cells. In contrast to previous reports,
Green and colleagues recently proposed that Bok-induced apoptosis
is not inhibited by anti-apoptotic Bcl-2 proteins, although a
potential antagonistic effect of A1 had not been explored (Llambi
et al., 2016). Moreover, the authors proposed that Bok does not
interact with BH3 proteins, but had an autonomous role in apoptosis
induction, although only a limited number of BH3-only proteins
were tested in that study. Furthermore, because the interaction of
Bok with BH3-only proteins or BH3 peptides has been mostly
studied in vitro, either by following the permeabilization of
unilamellar vesicles or by measuring surface plasmon resonance,
the exact positioning of Bok within the Bcl-2 network warrants
further investigation.
The detailed mechanism of how multidomain Bcl-2 proteins
cause mitochondrial outer membrane permeabilization (MOMP)
to trigger cytochrome c release is still under debate. Here, we have
established Bok not only as a modulator of apoptosis sensitivity but,
moreover, as a bona fide pro-apoptotic multidomain protein
that autonomously mediates MOMP and cytochrome c release.
Future studies are required to shed further light into several aspects
of Bok biology, including its position in the Bcl-2 network, its
functional difference to the Bax and Bak homologs, its putative
tumor suppressor function and its suitability for targeted cancer
therapy.
MATERIALS AND METHODS
Cell culture
The ovarian cancer cell lines OVCAR-3, -4 and -8 as well as HCT116, and
MCF7 cells were from the authenticated NCI60 panel of cancer cell lines
and obtained from the NCI Developmental Therapeutics Program. OVCAR-
3, OVCAR-8 and OVCAR-8 Bok−/− cells were maintained in RPMI-1640
medium (Sigma), supplemented with 10% fetal calf serum (FCS; PAA
Laboratories) and antibiotics (MycoZapPlus-CL; Lonza). OVCAR-3 cells
additionally received 2 mM glutamine (Life Technologies), whereas
OVCAR-4 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma) containing 10% tetracycline-free FCS (Life
Technologies), 1× MEM non-essential amino acids (PAA Laboratories)
and antibiotics. Primary baby mouse kidney (BMK) epithelial cells from
Bax−/−/Bak−/− mice (kindly provided by David Andrews, Department of
Biochemistry, Sunnybrook Research Institute, University of Toronto, ON,
Canada), authenticated Bax−/−/Bak−/− murine embryonic fibroblasts,
HEK293 cells and SH-SY5Y neuroblastoma cells (Janssen et al., 2007)
were obtained from the ATCC and maintained in DMEM supplemented
with 10% FCS, 1× MEM non-essential amino acids and antibiotics.
HCT116/wt and HCT116/Bax−/−/Bak−/− cells (kindly provided by Richard
Youle, Surgical Neurology Branch, National Institute of Neurological
Disorders and Stroke, Bethesda, MD) were cultured in McCoy’s 5A
medium (Life Technologies) with 10% FCS and antibiotics. All cells were
cultured at 37°C in a humidified 5% CO2 atmosphere. Bax and Bak
deficiency of the Bax- and Bak-deficient MEFs, BMK and HCT116 cells
was verified by immunoblot analysis. Cells were routinely tested for
contamination.
Transfection and drug treatment
BMK cells (3×105 cells/well) were seeded 24 h before transfection in six-
well plates. Transfection was performed with FuGENE 6 (Promega,
Mannheim, Germany) according to the manufacturer’s protocol using 3 µl
FuGENE 6 and 1 µg of the following plasmid DNAs: pEGFP-C1 empty
vector, pEGFP-C1-Bok, pEGFP-C1-Bak and pEGFP-C1-Bax. At 24 h and
48 h after transfection cells were stained and analyzed by flow cytometry.
OVCAR-8/wt and OVCAR-8/Bok−/− cell lines were seeded in six-well
plates at a density of 2×105 cells/well. After 24 h, the following cytostatic
agents were added to the cells: cisplatin (40 µM), taxol (0.1 µM) and
camptothecin (1 µM). After an additional 24 h, or 48 h for taxol, cells were
analyzed by flow cytometry.
Knockdown, induction of cell death and caspase activity assay
OVCAR-8, OVCAR-4, OVCAR-3 or SH-SY5Y cells were seeded
24 h before transfection in six-well plates at a density of 1×105 cells/well.
For siRNA transfection Bok, Bak and Bax ON-TARGET Plus Smartpool
siRNAs or non-targeted (NT) Smartpool ON-TARGET plus control siRNA
(GE Healthcare, Munich, Germany) were delivered using Dharmafect Ι
reagent (GE Healthcare) according to the manufacturer’s protocol.
At 48 h after transfection, cells were treated with the indicated
chemotherapeutic drugs. After an additional 24 h, or 48 h for taxol after,
cells were collected by scraping, washed with PBS and resuspended in 1 ml
PBS. Aliquots of the cell suspension were used to assess cell death by
annexin V and propidium iodide staining or caspase-3 and -7 activity in the
Caspase-Glo 3/7 assay (Promega) as described previously (Gillissen et al.,
2013; Volkmann et al., 2007). Successful knockdown was verified by
immunoblot analysis.
Generation of OVCAR-8/Bok−/− cell lines using TALEN constructs
TALEN constructs targeting human Bok and a corresponding mRFP or
GFP reporter construct were obtained from ToolGen Genome Engineering
(Seoul, Korea). OVCAR-8 cells were seeded 1 day before transfection in
six-well plates at a density of 2×105 cells/well. Transfection was
performed at a DNA:FuGENE 6 ratio of 1:3 using 1 µg of the
plasmids Human-BOK_TALEN_L1, Human-BOK_TALEN_R1 and
Human-BOK-RG2S1. At 40 h after transfection cells were trypsinized,
washed and resuspended in PBS. With fluorescence-activating cell
sorting, GFP-positive cells were sorted as single cells in 96-well plates.
Three clonal cell lines (clone 1, 2 and 3) were used for further
experiments and verified for loss of Bok expression by immunoblotting
and DNA sequence analyses.
Immunoblot analysis
Immunoblot analyses were performed as described previously (Essmann
et al., 2003). Cells were harvested by scraping, washed with ice-cold PBS
and resuspended with lysis buffer (1% Triton X-100, 10 mM Tris-HCl pH
7.5, 150 mM NaCl, 2 mMMgCl2 and 5 mM EDTA, pH 8.0) supplemented
with Halt™ Protease Inhibitor Cocktail (Thermo Fisher Scientific, Bonn,
Germany). Protein concentrations were determined using the BCA assay kit
(Thermo Fisher Scientific). Protein lysates were mixed with 5× Laemmli
buffer (300 mM Tris-HCl pH 6.8, 40% glycerol, 4% SDS and 3%
2-mercaptoethanol) and heated for 10 min at 95°C. Then, 15–30 µg of
proteins were separated on SDS-PAGE gels at 120 V. After electrophoresis,
proteins were transferred onto polyvinylidene difluoride membranes
(Amersham, GE Healthcare) by tank blotting (90 V, 2 h). Membranes
were blocked in blocking buffer (5% BSA, 0.1% Tween-20 in PBS) for 1 h,
followed by an overnight incubation with primary antibodies (1:1000) in
blocking buffer at 4°C. Primary antibodies used were rabbit anti-Bak (NT,
06-536) and anti-Bax (NT, 06-499; both fromMerckMillipore), mouse anti-
Bcl-2 (clone C-2) and anti-GFP (clone B-2, both from Santa Cruz
Biotechnology), mouse anti-Bcl-xL (clone 44) and anti-Mcl-1 (clone 22;
both from Becton Dickinson); goat anti-caspase-3 (AF-605-NA; R&D
Systems), rabbit anti-Bcl-w (clone 31H4), rabbit anti-caspase-3 (clone
8G10), rabbit anti-lamin A/C (clone 2032) and rabbit anti-Mcl-1
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(clone D35A5; all from Cell Signaling Technology); mouse anti-α-tubulin
(clone DM1A; Sigma) and monoclonal rabbit anti-Bok (1:500, BOK-1-5;
Echeverry et al., 2013; a kind gift from Thomas Kaufmann, Institute of
Pharmacology, University of Bern, Bern, Switzerland). Secondary
antibodies coupled to horseradish peroxidase (1:10,000; Promega) and
ECL reagents were used to detect proteins by chemoluminescence.
Immunofluorescence microscopy
Cells were seeded on coverslips in 12-well plates at 48 h before transfection
using 1.5 µg plasmid DNA and 4.5 µl FuGENE 6 in 100 µl OptiMEM.
After 16 h, cells were fixed with 4% formaldehyde for 30 min on ice,
washed with PBS, and followed by incubation for 1 h in blocking buffer
(4% BSA and 0.05% saponin in PBS) at room temperature. The cells were
then incubated overnight at 4°C with the following primary antibodies
diluted 1:500 in blocking buffer: rabbit anti-Tom20 (sc-11415; Santa Cruz
Biotechnology), mouse anti-cytochrome c (clone 6H2.B4), mouse anti-
Tom20 (clone 29, BD Biosciences) and conformation-specific antibodies
against Bak and Bax (NT, 06-536 and 06-499; Merck Millipore). After
washing the cells in PBS and twice in blocking buffer, secondary antibodies
(Alexa-Fluor-568 or -405-conjugated goat anti-mouse-IgG or anti-rabbit-
IgG; 1:500 in PBS; Life Technologies) were added for 2 h at room
temperature. The cells were washed twice in PBS and incubated in PBS
containing 1 µg/ml 4′,6-diamidino-2-phenylindol (DAPI; Life
Technologies) for 2 min. Coverslips were washed in PBS and mounted in
fluorescence-mounting medium (DAKO). Images were taken using a Leica
DMI6000 fluorescence microscope with a 63× oil immersion objective, and
processed with Leica DFC365FX and MetaMorph Software (Leica,
Wetzlar, Germany).
Flow cytometric analyses
For TMRE staining (Sohn et al., 2006), cell supernatant was collected, cells
were trypsinized, re-combined with supernatant and washed with RPMI
without Phenol Red (Life Technologies) supplemented with 2% FCS. Cells
were then incubated in RPMI with 2% FCS containing 400 nM TMRE
(Abcam) for 30 min at 37°C. After washing in cold PBS, cells were
resuspended in PBS containing 0.2% BSA and analyzed using a LSRII flow
cytometer (BD Biosciences). For annexin V staining, cells were harvested as
described above, washed twice in ice-cold PBS, resuspended in annexin-V-
binding buffer and incubated with 5 µl of APC- or FITC-coupled annexin V
(BD Biosciences) for 15 min at room temperature in the dark. Annexin V
and propidium iodide staining was performed as described previously
(Gillissen et al., 2013). For Sytox Red staining, culture supernatant was
collected, cells were washed in Hank’s Balanced Salt Solution (Life
Technologies), trypsinized and combined with supernatant. After washing
cells were resuspended in HBSS containing 6 nM Sytox Red Dead Cell
Stain (Life Technologies) and incubated for 15 min at room temperature in
the dark. Flow cytometric quantification of cytochrome c release was carried
out as described previously (Waterhouse and Trapani, 2003; Janssen et al.,
2009). EGFP-positive cells were analyzed by flow cytometry.
Statistical analysis
Statistical significance of data was assessed by unpaired two-tailed
Student’s t-test using GraphPad Prism 5.0f software (GraphPad Software
Inc., La Jolla, CA, USA). P values of <0.05 were considered significant.
Acknowledgements
We thank D. Andrews, E. White and R. Youle for cell lines, T. Kaufmann for the Bok
antibody and Antje Richter, Anja Richter and M. Grimm for expert technical
assistance.
Competing interests
The authors declare no competing or financial interests.
Author contributions
S.E.-S. designed and performed experiments, analyzed and interpreted data and
participated in writing the manuscript. S.M., K.B., D.S., J.J., and M.M. performed
experiments. P.T.D. and B.F.G. participated in conceptual design and wrote the
manuscript. F.E. and K.S.-O. designed experiments, analyzed and interpreted data,
and wrote the manuscript.
Funding
This work was supported by grants from the Deutsche Forschungsgemeinschaft
[grant numbers SFB685 to K.S.-O., GRK1302 to K.S.-O.]; and the Deutsche
Krebshilfe [grant number 109894 to F.E.].
Supplementary information
Supplementary information available online at
http://jcs.biologists.org/lookup/suppl/doi:10.1242/jcs.181727/-/DC1
References
Beroukhim, R., Mermel, C. H., Porter, D., Wie, G., Raychaudhuri, S., Donovan,
J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M. et al. (2010). The
landscape of somatic copy-number alteration across human cancers.Nature 463,
899-905.
Carpio, M. A., Michaud, M., Zhou, W., Fisher, J. K., Walensky, L. D. and Katz,
S. G. (2015). BCL-2 family member BOK promotes apoptosis in response to
endoplasmic reticulum stress. Proc. Natl. Acad. Sci. USA 112, 7201-7206.
Chi, X., Kale, J., Leber, B. andAndrews, D.W. (2014). Regulating cell death at, on,
and in membranes. Biochim. Biophys. Acta 1843, 2100-2113.
Czabotar, P. E., Lessene, G., Strasser, A. and Adams, J. M. (2014). Control of
apoptosis by the BCL-2 protein family: implications for physiology and therapy.
Nat. Rev. Mol. Cell Biol. 15, 49-63.
Degenhardt, K., Sundararajan, R., Lindsten, T., Thompson, C. and White, E.
(2002). Bax and Bak independently promote cytochrome C release from
mitochondria. J. Biol. Chem. 277, 14127-14134.
Delbridge, A. R. D., Grabow, S., Strasser, A. and Vaux, D. L. (2016). Thirty years
of BCL-2: translating cell death discoveries into novel cancer therapies. Nat. Rev.
Cancer 16, 99-109.
Du, H., Wolf, J., Schafer, B., Moldoveanu, T., Chipuk, J. E. and Kuwana, T.
(2011). BH3 domains other than Bim andBid can directly activate Bax/Bak. J. Biol.
Chem. 286, 491-501.
Echeverry, N., Bachmann, D., Ke, F., Strasser, A., Simon, H. U. and Kaufmann,
T. (2013). Intracellular localization of the BCL-2 family member BOK and
functional implications. Cell Death Differ. 20, 785-799.
Essmann, F., Bantel, H., Totzke, G., Engels, I. H., Sinha, B., Schulze-Osthoff, K.
and Jänicke, R. U. (2003). Staphylococcus aureus alpha-toxin-induced cell
death: predominant necrosis despite apoptotic caspase activation. Cell Death
Differ. 10, 1260-1272.
Fernandez-Marrero, Y., Ke, F., Echeverry, N., Bouillet, P., Bachmann, D.,
Strasser, A. and Kaufmann, T. (2016). Is BOK required for apoptosis induced by
endoplasmic reticulum stress? Proc. Natl. Acad. Sci. USA 113, E492-E493.
Gao, S., Fu, W., Dürrenberger, M., De Geyter, C. and Zhang, H. (2005).
Membrane translocation and oligomerization of hBok are triggered in response to
apoptotic stimuli and Bnip3. Cell. Mol. Life Sci. 62, 1015-1024.
Gillissen, B., Essmann, F., Hemmati, P. G., Richter, A., Richter, A., Öztop, I.,
Chinnadurai, G., Dörken, B. and Daniel, P. T. (2007). Mcl-1 determines the Bax
dependency of Nbk/Bik-induced apoptosis. J. Cell Biol. 179, 701-715.
Gillissen, B., Richter, A., Richter, A., Overkamp, T., Essmann, F., Hemmati,
P. G., Preissner, R., Belka, C. and Daniel, P. T. (2013). Targeted therapy of the
XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by
switching apoptosis signaling to a Bax/Bak-independent ‘type I’ mode. Cell
Death Dis. 4, e643.
Hsu, S. Y., Kaipia, A., McGee, E., Lomeli, M. and Hsueh, A. J. W. (1997). Bok is a
pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and
heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc. Natl.
Acad. Sci. USA 94, 12401-12406.
Inohara, N., Ekhterae, D., Garcia, I., Carrio, R., Merino, J., Merry, A., Chen, S.
and Nún ̃ez, G. (1998). Mtd, a novel Bcl-2 family member activates apoptosis in
the absence of heterodimerization with Bcl-2 and Bcl-XL. J. Biol. Chem. 273,
8705-8710.
Jabbour, A. M., Heraud, J. E., Daunt, C. P., Kaufmann, T., Sandow, J., O’Reilly,
L. A., Callus, B. A., Lopez, A., Strasser, A., Vaux, D. L. et al. (2008). Puma
indirectly activates Bax to cause apoptosis in the absence of Bid or Bim. Cell
Death Differ. 16, 555-563.
Janssen, K., Pohlmann, S., Jänicke, R. U., Schulze-Osthoff, K. and Fischer, U.
(2007). Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled
pathway and promotes clonogenic survival during paclitaxel treatment.Blood 110,
3662-3672.
Janssen, K., Horn, S., Niemann, M. T., Daniel, P. T., Schulze-Osthoff, K. and
Fischer, U. (2009). Inhibition of the ER Ca2+ pump forces multidrug-resistant
cells deficient in Bak and Bax into necrosis. J. Cell Sci. 122, 4481-4491.
Ke, F., Voss, A., Kerr, J. B., O’Reilly, L. A., Tai, L., Echeverry, N., Bouillet, P.,
Strasser, A. and Kaufmann, T. (2012). BCL-2 family member BOK is widely
expressed but its loss has only minimal impact in mice. Cell Death Differ. 19,
915-925.
Ke, F., Bouillet, P., Kaufmann, T., Strasser, A., Kerr, J. and Voss, A. K. (2013).
Consequences of the combined loss of BOK and BAK or BOK and BAX. Cell
Death Dis. 4, e650.
2222
RESEARCH ARTICLE Journal of Cell Science (2016) 129, 2213-2223 doi:10.1242/jcs.181727
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
Koopman, G., Reutelingsperger, C. P., Kuijten, G. A., Keehnen, R. M., Pals, S. T.
and van Oers, M. H. (1994). Annexin V for flow cytometric detection of
phosphatidylserine expression on B cells undergoing apoptosis. Blood 84,
1415-1420.
Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A.,
Green, D. R. and Newmeyer, D. D. (2005). BH3 domains of BH3-only proteins
differentially regulate Bax-mediated mitochondrial membrane permeabilization
both directly and indirectly. Mol. Cell 17, 525-535.
Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir,
S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M. et al. (2015). Exploiting
selective BCL-2 family inhibitors to dissect cell survival dependencies and define
improved strategies for cancer therapy. Sci. Transl. Med. 7, 279ra240.
Lindsten, T., Ross, A. J., King, A., Zong, W.-X., Rathmell, J. C., Shiels, H. A.,
Ulrich, E., Waymire, K. G., Mahar, P., Frauwirth, K. et al. (2000). The combined
functions of proapoptotic Bcl-2 family members bak and bax are essential for
normal development of multiple tissues. Mol. Cell 6, 1389-1399.
Llambi, F., Moldoveanu, T., Tait, S. W. G., Bouchier-Hayes, L., Temirov, J.,
McCormick, L. L., Dillon, C. P. and Green, D. R. (2011). A unified model of
mammalian BCL-2 protein family interactions at the mitochondria. Mol. Cell 44,
517-531.
Llambi, F., Wang, Y.-M., Victor, B., Yang, M., Schneider, D. M., Gingras, S.,
Parsons, M. J., Zheng, J. H., Brown, S. A., Pelletier, S. et al. (2016). BOK is a
non-canonical BCL-2 family effector of apoptosis regulated by ER-associated
degradation. Cell 165, 421-433.
Los, M., Wesselborg, S. and Schulze-Osthoff, K. (1999). The role of caspases in
development, immunity, and apoptotic signal transduction: lessons from knockout
mice. Immunity 10, 629-639.
Moldoveanu, T., Follis, A. V., Kriwacki, R. W. and Green, D. R. (2014). Many
players in BCL-2 family affairs. Trends Biochem. Sci. 39, 101-111.
Neise, D., Graupner, V., Gillissen, B. F., Daniel, P. T., Schulze-Osthoff, K.,
Janicke, R. U. and Essmann, F. (2008). Activation of the mitochondrial death
pathway is commonly mediated by a preferential engagement of Bak. Oncogene
27, 1387-1396.
Ricci, J.-E., Gottlieb, R. A. and Green, D. R. (2003). Caspase-mediated loss of
mitochondrial function and generation of reactive oxygen species during
apoptosis. J. Cell Biol. 160, 65-75.
Shamas-Din, A., Kale, J., Leber, B. and Andrews, D. W. (2013). Mechanisms of
action of Bcl-2 family proteins. Cold Spring Harb. Perspect. Biol. 5, a008714.
Sohn, D., Essmann, F., Schulze-Osthoff, K. and Jänicke, R. U. (2006). p21
blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of
cyclin-dependent kinase-mediated caspase-9 activation. Cancer Res. 66,
11254-11262.
Sun, N. and Zhao, H. (2013). Transcription activator-like effector nucleases
(TALENs): a highly efficient and versatile tool for genome editing. Biotechnol.
Bioeng. 110, 1811-1821.
Volkmann, X., Fischer, U., Bahr, M. J., Ott, M., Lehner, F., MacFarlane, M.,
Cohen, G. M., Manns, M. P., Schulze-Osthoff, K. and Bantel, H. (2007).
Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing
ligand in diseased human liver. Hepatology 46, 1498-1508.
Wang, C. and Youle, R. J. (2012). Predominant requirement of Bax for apoptosis in
HCT116 cells is determined by Mcl-1’s inhibitory effect on Bak. Oncogene 31,
3177-3189.
Waterhouse, N. J. and Trapani, J. A. (2003). A new quantitative assay for
cytochrome c release in apoptotic cells. Cell Death Differ. 10, 853-855.
Wei, M. C., Zong, W.-X., Cheng, E. H.-Y., Lindsten, T., Panoutsakopoulou, V.,
Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B. and Korsmeyer,
S. J. (2001). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial
dysfunction and death. Science 292, 727-730.
Westphal, D., Kluck, R. M. andDewson, G. (2014). Building blocks of the apoptotic
pore: howBax and Bak are activated and oligomerize during apoptosis.Cell Death
Differ. 21, 196-205.
Willis, S. N., Chen, L., Dewson, G., Wie, A., Naik, E., Fletcher, J. I., Adams, J. M.
and Huang, D. C. S. (2005). Proapoptotic Bak is sequestered by Mcl-1 and Bcl-
xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 19,
1294-1305.
Willis, S. N., Fletcher, J. I., Kaufmann, T., van Delft, M. F., Chen, L., Czabotar,
P. E., Ierino, H., Lee, E. F., Fairlie, W. D., Bouillet, P. et al. (2007). Apoptosis
initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak.
Science 315, 856-859.
Zhang, H., Holzgreve, W. and De Geyter, C. (2000). Evolutionarily conserved Bok
proteins in the Bcl-2 family. FEBS Lett. 480, 311-313.
2223
RESEARCH ARTICLE Journal of Cell Science (2016) 129, 2213-2223 doi:10.1242/jcs.181727
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
J. Cell Sci. 129: doi:10.1242/jcs.181727: Supplementary information
Fig. S1: Bok localizes to mitochondria and the ER. (A) HEK293 and MCF7 cells were 
transfected with expression constructs for EGFP or EGFP-Bok, before cell lysates were 
separated by centrifugation (10,000g) in a cytosolic and a mitochondria-enriched heavy 
membrane fraction (HMF). Western blot reveals predominant localization of EGFP in 
GAPDH-containing cytosolic fractions, whereas EGFP-Bok is enriched in Tom20-containing 
mitochondrial fractions. (B) Immunofluorescence 
 microscopy shows that EGFP-Bok partially localizes at mitochondria (Tom20) and ER 
(calnexin) and only marginally at the Golgi apparatus (GM130). (C) Expression of mCherry-
Bok mediates release of cytochrome c from mitochondria (Tom20) in Bax/Bak-deficient 
murine embryonic fibroblasts (MEF) as shown by immunofluorescence microscopy. 
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Fig. S2: Bok induces cells death less potently than Bax and Bak in BMK cells. BMK cells 
were transfected with expression vectors for EGFP or EGFP fusion proteins of Bax, Bak and 
Bok, and apoptosis was measured by flow cytometric annexin V staining. As indicated by the 
gating for the EGFP signal, annexin V staining was assessed in four cell populations with 
different levels of EGFP expression (left panel). Results (right panel) show that at different 
ranges of similar EGFP signal intensity the number of annexin V-positive cells is lower in 
EGFP-Bok expressing cells as compared to EGFP-Bak and -Bax expressing cells.  
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Fig. S3: Expression of EGFP-Bok and FLAG-Bok mediates enhanced DEVDase activity 
in Bax/Bak-deficient BMK cells. BMK cells were transfected with vectors for the expression 
of EGFP-Bok, FLAG-Bok or the respective vector controls. (A) As measured by the kinetics 
of cleavage of a luminometric DEVD substrate in the Caspase 3/7 Glo assay, extracts from 
EGFP-Bok and Flag-Bok expressing cells show enhanced cleavage of a luminometric DEVD 
substrate as compared to controls. (B) DEVDase activity normalized for protein content in 
extracts from cells expressing EGFP-Bok or FLAG-Bok (lower panel). RLU: relative light 
units. 
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Fig. S4: Verification of the TALEN-mediated Bok knockout by DNA sequence analysis. 
Sequencing of genomic DNA from OVCAR-8 wildtype and the three OVCAR-8/Bok-/- cell 
clones shows a premature stop codon at the TALEN target site. 
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